Jeffrey Burnett, DO
Internal Medicine · Williamsville, NYNPI 1346226271
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 515 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 47 manufacturers, the largest accounting for just 10.1% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 515 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$916
- Pfizer$844
- Gilead$568
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$537
- Lilly USA, LLC$516
- Johnson & Johnson$485
- plus $5K from 41 others
Across 49 payments — averaging $6993.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$271K
- AstraZeneca$44K
- Amgen$28K
What the payments were for
- Food & beverage$9,034100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$9,035 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 108 | $122,411 |
| OzempicSemaglutide | 89 | $95,649 |
| EliquisApixaban | 74 | $52,820 |
| FarxigaDapagliflozin Propanediol | 28 | $29,089 |
| MounjaroTirzepatide | 18 | $26,613 |
| RybelsusSemaglutide | 21 | $25,637 |
| XareltoRivaroxaban | 26 | $24,578 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $16,859 |
| TradjentaLinagliptin | 20 | $14,940 |
| TrulicityDulaglutide | 16 | $14,756 |
| Spiriva RespimatTiotropium Bromide | 19 | $11,547 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 79 | $10,156 |
| SynthroidLevothyroxine Sodium | 100 | $9,102 |
| LinzessLinaclotide | 14 | $8,423 |
| Icosapent Ethyl | 29 | $8,251 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $468 | $148,898147 claims |
| Novo NordiskOzempic, Rybelsus | $916 | $121,286110 claims |
| PfizerEliquis | $844 | $52,82074 claims |
| Lilly USA, LLCMounjaro, Trulicity | $516 | $41,36934 claims |
| AstraZenecaFarxiga, Symbicort | $117 | $36,36653 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $202 | $29,12045 claims |
| Johnson & JohnsonXarelto | $485 | $24,57826 claims |
| AbbVieSynthroid, Linzess | $410 | $17,525114 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $28 | $6,264364 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $144 | $3,34716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Williamsville
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.